Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

por Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter
Publicado 2020

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

por Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques
Publicado 2017

Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase

por Behshad, Elham, Klabe, Ronald M., Margulis, Alexander, Becker-Pasha, Mary, Rupar, Mark J., Collier, Paul, Liu, Phillip C., Hollis, Gregory F., Burn, Timothy C., Wynn, Richard
Publicado 2010

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents

por Wang, Liang-Chuan S, Koblish, Holly, Hansbury, Michael, Zhang, Yue, Yang, Gengjie, Burn, Timothy, Waeltz, Paul, Rupar, Mark, Yue, Eddy, Douty, Brent, Maduskuie, Thomas, Falahatpisheh, Nikoo, Li, Yun-Long, Combs, Andrew P, Hollis, Gregory, Huber, Reid, Scherle, Peggy
Publicado 2015

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients

por Emtenani, Shirin, Holtsche, Maike M., Stahlkopf, Richard, Seiler, Daniel L., Burn, Timothy, Liu, Huiqing, Parker, Melissa, Yilmaz, Kaan, Dikmen, Hasan O., Lang, Markus Huber, Sadik, Christian D., Karsten, Christian M., van Beek, Nina, Ludwig, Ralf J., Köhl, Jörg, Schmidt, Enno
Publicado 2022

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

por Neumann, Olaf, Burn, Timothy C., Allgäuer, Michael, Ball, Markus, Kirchner, Martina, Albrecht, Thomas, Volckmar, Anna-Lena, Beck, Susanne, Endris, Volker, Goldschmid, Hannah, Lehmann, Ulrich, Seker-Cin, Huriye, Uhrig, Sebastian, Roessler, Stephanie, Budczies, Jan, Fröhling, Stefan, Longerich, Thomas, Wagner, Alex H., Vogel, Arndt, Schirmacher, Peter, Stenzinger, Albrecht, Kazdal, Daniel
Publicado 2022

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

por Yue, Eddy W., Sparks, Richard, Polam, Padmaja, Modi, Dilip, Douty, Brent, Wayland, Brian, Glass, Brian, Takvorian, Amy, Glenn, Joseph, Zhu, Wenyu, Bower, Michael, Liu, Xiangdong, Leffet, Lynn, Wang, Qian, Bowman, Kevin J., Hansbury, Michael J., Wei, Min, Li, Yanlong, Wynn, Richard, Burn, Timothy C., Koblish, Holly K., Fridman, Jordan S., Emm, Tom, Scherle, Peggy A., Metcalf, Brian, Combs, Andrew P.
Publicado 2017

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

por Liu, Phillip C. C., Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A., Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C., Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory
Publicado 2020

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022